-
Vascular Health and Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The interleukin-6 –174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study
Original Research
(2489) Views (406) Full article downloads
Authors: Mark PS Sie, Francesco US Mattace-Raso, André G Uitterlinden, Pascal P Arp, Albert Hofman, et al
Published Date September 2008
Volume 2008:4(4) Pages 863 - 869
DOI: http://dx.doi.org/10.2147/VHRM.S1693
Mark PS Sie1, Francesco US Mattace-Raso2, André G Uitterlinden2, Pascal P Arp2, Albert Hofman1, Huibert AP Pols2, Arnold PG Hoeks3, Robert S Reneman4, Roland Asmar5, Cornelia M van Duijn1, Jacqueline CM Witteman1
1Department of Epidemiology and Biostatistics, 2Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; 3Department of Biophysics, 4Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; 5Cardiovascular Institute, Paris, France
Abstract: Arterial stiffness normally increases with age and has been established as a precursor of cardiovascular disease. Interleukin-6 is a pleiotropic inflammatory cytokine with an important role in the inflammatory cascade, such as up-regulation of C-reactive protein (CRP). The interleukin-6 –174-G/C promoter polymorphism appears to infl uence levels of inflammatory markers, which have been shown to be associated with arterial stiffness. We studied the association of this polymorphism with levels of interleukin-6 and CRP and with arterial stiffness. The study (n = 3849) was embedded in the Rotterdam Study, a prospective, population-based study. Analyses on the association between the –174-G/C polymorphism and pulse wave velocity, distensibility coefficient, and pulse pressure were performed using analyses of variance. Analyses on the levels of inflammatory markers and arterial stiffness were performed using linear regression analyses. Analyses were adjusted for age, sex, mean arterial pressure, heart rate, known cardiovascular risk factors, and atherosclerosis. We found pulse wave velocity to be 0.35 m/s higher for CC-homozygotes vs. wildtype GG-homozygotes (p = 0.018) with evidence for an allele-dose effect (p trend = 0.013), and a similar pattern for pulse pressure (p trend = 0.041). No apparent consistent association with the distensibility coefficient was found. CRP levels were associated with pulse wave velocity (p = 0.007). In conclusion, the interleukin-6 –174 G/C polymorphism is associated with increased arterial stiffness and pulse pressure.
Keywords: IL-6, CRP, arterial stiffness, pulse wave velocity, distensibility coefficient, pulse pressure
Readers of this article also read:
Urotensin II in cardiovascular regulation
The renin–angiotensin system and diabetes: An update
TNF-α-mediated inflammation in cerebral aneurysms: A potential link to growth and rupture
Utility of ranolazine in chronic stable angina patients
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Corrigendum
Erratum
A case of recurrent bloody tears
- Join ISVH
Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- The western diet and lifestyle and diseases of civilization
- Stiffness of the large arteries in individuals with and without Down syndrome
- Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review




